NuVasive Restructures Commercialization Leadership Team

When announcing recent new commercialization roles for three members of its executive team, NuVasive reiterated its intent to transform global operations and drive efficiencies through the combination of manufacturing, supply chain, information technology, regulatory affairs and quality assurance. 

The words “combination of” stand out to me at a time when so much of our writing and expressed opinions of seasoned leaders have repeated the importance of breaking down silos—making yourself familiar with the decisions taking place next to, above and below you. A collaborative environment is essential when the work is complex. Too often, a seemingly inconsequential change at the manufacturing level can create major regulatory hurdles, or a miscommunication with a supplier results in costly quality issues. The examples are endless—I’m certain you have your own. 

NuVasive committed to bring its manufacturing in-house and to surpass $1 billion in revenue in 2017; therefore, the company needs a level of alignment within these divisions. Still, exactly how this “global operations transformation” unfolds will be interesting to watch. How will supply chain, regulatory and quality teams deliver on their own objectives while assisting each other achieve cross-functional goals? We’ll be looking for lessons that can be learned and adopted, especially from a supply chain and operations standpoint.

For now, here are the new titles and responsibilities of three NuVasive executives who will lead the charge to refine the company’s operating structure and align strategy throughout the commercialization channel. 

Steve Rozow was elevated to the role of Executive Vice President Global Process Transformation, adding IT and RA/QA to his current responsibilities of Global Operations. Mr. Rozow led the development of NuVasive’s new manufacturing facility, as well as supply chain and fulfillment improvements. He joined the company in 2015 and most notably spent 20 years with Zimmer.

Skip Kiil was named Executive Vice President, Global Commercial and will play an integral role in doubling NuVasive’s international market share in the coming years while expanding its U.S. presence. Mr. Kiil, who joined the company in June, previously worked at Stryker and Alcon, managing and growing global operations.

Matt Link was promoted to the newly-created position Executive Vice President, Strategy, Technology and Corporate Development. Building upon more than 15 years with the company, Mr. Link will lead product and systems development, global marketing, surgeon education, clinical research and corporate development.

Additionally, Jason Hannon, President and Chief Operating Officer, and Quentin Blackford, Chief Financial Officer, have left the company. Mr. Hannon has moved on to lead Mainstay Medical, and Mr. Blackford is pursuing an opportunity outside of spine.

NuVasive’s Chief Executive Officer Gregory T. Lucier made the announcements in the 2Q earnings call, stating that Mr. Hannon’s departure accelerated the company’s timeline to implement these organizational changes.

NuVasive posted 1H17 revenue of $510.4MM, +13.1%. Leadership has maintained its confidence in their full-year revenue guidance of $1.0BB+.